Tango Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +39.0%
EBITDA: +25.3%
EBIT: +19.4%
EPS: +31.4%
Free cash flow: -4.8%
Operating cash flow: -4.6%

Forward estimates

Revenue: +200.6%
EBITDA: -62.9%
EPS: -68.7%

Three-year CAGR

Revenue: +35.9%
EBITDA: +22.2%
EBIT: +23.6%
Net income: +22.0%
EPS: +26.9%
Free cash flow: -5.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.